Update on Phase I/II study of azacitidine, venetoclax and gilteritinib in patients with FLT3+ AML

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AMLПодробнее

Nicholas Short, MD, Discusses Triplet Combination for FLT3-mutated AMLПодробнее

Triplet combination of azacitidine, venetoclax & gilteritinib for patients with FLT3-mutated AMLПодробнее

Azacitidine, venetoclax and gilteritinib in previously untreated and R/R FLT3-mutated AMLПодробнее

Azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukaemiaПодробнее

Gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed FLT3-mutated AMLПодробнее

Patient-reported outcomes in FLT3-mutated AML patients treated with gilteritinib plus azacitidineПодробнее

The promise of combining venetoclax with gilteritinib for the treatment of FLT3-mutated AMLПодробнее

A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AMLПодробнее

Venetoclax plus azacitidine in FLT3-mutated AMLПодробнее

Gilteritinib plus venetoclax for R/R FLT3-mutated AMLПодробнее

Phase I trial results for oral azacitidine and venetoclax in R/R AMLПодробнее

Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AMLПодробнее

Phase II study of venetoclax and azacitidine vs induction chemotherapy in fit patients with AMLПодробнее

Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AMLПодробнее

Phase III trial of azacitidine and gilteritinib in FLT3 mutant AMLПодробнее

Phase Ib/II study of magrolimab in combination with azacitidine and venetoclax in patients with AMLПодробнее

Results of a Phase II study of gilteritinib versus midostaurin in newly diagnosed FLT3-mutated AMLПодробнее

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with flt3-mutated re...Подробнее